郑州微飒生物科技有限责任公司 咨询热线：0371-88821766
行业动态

行业动态

追踪行业前沿，洞察产业趋势

药效评价ST 1535: a preferential A2A adenosine receptor antagonist.

期刊：The international journal of neuropsychopharmacology发表年份：2006作者：Maria Antonietta Stasi; Franco Borsini; Katia Varani; Fabrizio Vincenzi; Maria Assunta Di Cesare; Patrizia Minetti; Orlando Ghirardi; Paolo Carminati
阅读更多 →

药效评价Validation of using gene expression in mononuclear cells as a marker for hepatic cholesterol metabolism.

期刊：Lipids in health and disease发表年份：2006作者：Dimple Aggarwal; Hedley C Freake; Ghada A Soliman; Amrita Dutta; Maria-Luz Fernandez
阅读更多 →

药效评价Dibenzazecine compounds with a novel dopamine/5HT2A receptor profile and 3D-QSAR analysis.

期刊：BMC pharmacology发表年份：2006作者：Alexandra Hamacher; Mathias Weigt; Michael Wiese; Barbara Hoefgen; Jochen Lehmann; Matthias U Kassack
阅读更多 →

药效评价Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists.

期刊：Molecular pharmacology发表年份：2006作者：Michael R Braden; Jason C Parrish; John C Naylor; David E Nichols
阅读更多 →